Zoetis (ZTS) to Release Quarterly Earnings on Thursday

Zoetis (NYSE:ZTS) is expected to issue its Q4 2025 results before the market opens on Thursday, February 12th. Analysts expect Zoetis to post earnings of $1.40 per share and revenue of $2.3612 billion for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, February 12, 2026 at 8:30 AM ET.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Tuesday, November 4th. The company reported $1.70 EPS for the quarter, topping analysts’ consensus estimates of $1.62 by $0.08. Zoetis had a return on equity of 57.19% and a net margin of 28.21%.The firm had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.42 billion. During the same quarter last year, the business posted $1.58 earnings per share. The firm’s revenue was up .5% compared to the same quarter last year. On average, analysts expect Zoetis to post $6 EPS for the current fiscal year and $7 EPS for the next fiscal year.

Zoetis Stock Up 3.5%

NYSE ZTS opened at $126.69 on Thursday. The business’s fifty day simple moving average is $124.00 and its 200-day simple moving average is $136.62. The company has a quick ratio of 2.28, a current ratio of 3.64 and a debt-to-equity ratio of 1.31. The firm has a market cap of $55.83 billion, a PE ratio of 21.33, a P/E/G ratio of 2.11 and a beta of 0.96. Zoetis has a 52 week low of $115.25 and a 52 week high of $177.40.

Zoetis Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 3rd. Stockholders of record on Tuesday, January 20th will be given a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a dividend yield of 1.7%. The ex-dividend date of this dividend is Tuesday, January 20th. This is a boost from Zoetis’s previous quarterly dividend of $0.50. Zoetis’s dividend payout ratio is presently 35.69%.

Wall Street Analyst Weigh In

ZTS has been the topic of several research reports. Morgan Stanley set a $160.00 price target on shares of Zoetis in a research report on Thursday, December 18th. Barclays began coverage on Zoetis in a research report on Monday, December 8th. They set an “equal weight” rating and a $136.00 price objective on the stock. UBS Group set a $136.00 price objective on Zoetis in a research note on Thursday, January 29th. BTIG Research reiterated a “buy” rating and set a $160.00 price target on shares of Zoetis in a report on Wednesday, December 3rd. Finally, HSBC set a $140.00 target price on Zoetis in a report on Wednesday, December 10th. Five analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $152.45.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in ZTS. Bellevue Group AG raised its stake in shares of Zoetis by 32.7% during the 3rd quarter. Bellevue Group AG now owns 872 shares of the company’s stock worth $128,000 after buying an additional 215 shares in the last quarter. Newbridge Financial Services Group Inc. raised its position in Zoetis by 23.7% in the third quarter. Newbridge Financial Services Group Inc. now owns 1,145 shares of the company’s stock worth $168,000 after acquiring an additional 219 shares in the last quarter. Headlands Technologies LLC purchased a new position in Zoetis in the second quarter worth $194,000. Boothbay Fund Management LLC acquired a new stake in Zoetis in the second quarter valued at $202,000. Finally, MUFG Securities EMEA plc purchased a new stake in shares of Zoetis during the 2nd quarter worth $206,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.